Find clinical trials for Non-Hodgkin Lymphoma in New York, NY
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Non-Hodgkin Lymphoma trials near New York, NY, USA:
ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...
Phase 1
New York, New York, United States and 7 other locations
radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are be...
Phase 1
Hackensack, New Jersey, United States and 2 other locations
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Hackensack, New Jersey, United States and 66 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Hackensack, New Jersey, United States and 89 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
New York, New York, United States and 73 other locations
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...
Phase 3
New York, New York, United States and 188 other locations
administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) admin...
Phase 1, Phase 2
New York, New York, United States and 12 other locations
The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Ho ...
Phase 1
New York, New York, United States
1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non...
Phase 1, Phase 2
New York, New York, United States and 8 other locations
Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL.Part 2: To characterize th...
Phase 1, Phase 2
New York, New York, United States and 31 other locations
Clinical trials
Research sites
Resources
Legal